![Garry Pairaudeau](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Garry Pairaudeau
Technik-/Wissenschafts-/F&E-Leiter bei Exscientia AI Ltd.
Profil
Garry Pairaudeau is currently the Chief Technology Officer at Exscientia AI Ltd.
He previously worked at AstraZeneca PLC as the Head-Hit Discovery from 2017 to 2020.
He also worked as the Chief Technology Officer at Exscientia Plc from 2020 to 2023.
Dr. Pairaudeau received his undergraduate and doctorate degrees from The University of Southampton.
Aktive Positionen von Garry Pairaudeau
Unternehmen | Position | Beginn |
---|---|---|
Exscientia AI Ltd.
![]() Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2020 |
Ehemalige bekannte Positionen von Garry Pairaudeau
Unternehmen | Position | Ende |
---|---|---|
EXSCIENTIA PLC | Technik-/Wissenschafts-/F&E-Leiter | 30.06.2023 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01.11.2020 |
Ausbildung von Garry Pairaudeau
The University of Southampton | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
EXSCIENTIA PLC | Health Technology |
ASTRAZENECA PLC | Health Technology |
Private Unternehmen | 1 |
---|---|
Exscientia AI Ltd.
![]() Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom. | Health Technology |